{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2010)
Source URL:
First approved in 2010
Source:
21 CFR 348
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M020
(2022)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT04160767: Phase 4 Interventional Unknown status Celiac Disease
(2019)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2011)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M014
(2019)
Source URL:
First approved in 2010
Source:
21 CFR 358F
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2010)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
First approved in 2010
Source:
ARMOUR THYROID by Rebel Distributors Corp
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2009)
Source URL:
First approved in 2009
Source:
21 CFR 333A
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M
(2009)
Source URL:
First approved in 2009
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 358H
(2009)
Source URL:
First approved in 2009
Source:
21 CFR 358H
Source URL:
Class:
MIXTURE